Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Free Cash Flow (2016 - 2025)

CytomX Therapeutics' Free Cash Flow history spans 12 years, with the latest figure at -$23.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 17.97% year-over-year to -$23.2 million; the TTM value through Dec 2025 reached -$75.6 million, up 12.35%, while the annual FY2025 figure was -$75.6 million, 12.35% up from the prior year.
  • Free Cash Flow reached -$23.2 million in Q4 2025 per CTMX's latest filing, down from -$15.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $9.3 million in Q1 2023 to a low of -$42.0 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$22.6 million, with a median of -$22.3 million recorded in 2023.
  • The largest YoY upside for Free Cash Flow was 122.12% in 2023 against a maximum downside of 1262.79% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$31.4 million in 2021, then soared by 94.99% to -$1.6 million in 2022, then crashed by 1262.79% to -$21.5 million in 2023, then grew by 8.28% to -$19.7 million in 2024, then decreased by 17.97% to -$23.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Free Cash Flow are -$23.2 million (Q4 2025), -$15.4 million (Q3 2025), and -$15.9 million (Q2 2025).